Celcuity’s (CELC) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research note released on Friday morning,Benzinga reports. They currently have a $27.00 target price on the stock.

CELC has been the subject of several other reports. Stifel Nicolaus upped their price target on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Leerink Partners began coverage on Celcuity in a research note on Monday, July 22nd. They issued an “outperform” rating and a $29.00 target price for the company. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research report on Friday. Finally, Lifesci Capital initiated coverage on shares of Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $29.17.

Celcuity Price Performance

Shares of NASDAQ CELC traded down $1.45 during trading hours on Friday, reaching $12.66. 954,227 shares of the stock traded hands, compared to its average volume of 279,872. The company’s 50-day simple moving average is $15.15 and its two-hundred day simple moving average is $16.03. The company has a market capitalization of $468.80 million, a P/E ratio of -4.62 and a beta of 0.76. Celcuity has a 52-week low of $11.51 and a 52-week high of $22.19. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. During the same quarter in the prior year, the firm earned ($0.66) EPS. Equities research analysts forecast that Celcuity will post -2.54 EPS for the current year.

Institutional Investors Weigh In On Celcuity

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its holdings in Celcuity by 78.5% in the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after buying an additional 3,930 shares during the period. Vanguard Group Inc. lifted its stake in shares of Celcuity by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock valued at $17,898,000 after purchasing an additional 7,821 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Celcuity during the first quarter valued at approximately $3,545,000. Baker BROS. Advisors LP grew its stake in Celcuity by 189.9% in the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock worth $33,534,000 after purchasing an additional 1,017,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after purchasing an additional 1,600 shares in the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.